Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shank, M. L.
Right arrow Articles by DeFronzo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shank, M. L.
Right arrow Articles by DeFronzo, R. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 44, Issue 2 165-172, Copyright © 1995 by American Diabetes Association

ARTICLES

Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM

ML Shank, S Del Prato and RA DeFronzo
Diabetes Division, University of Texas Health Science Center, San Antonio 78284.

Bedtime insulin (BI)/daytime sulfonylurea (DSU) therapy was studied double-blind in 30 non-insulin-dependent diabetes mellitus subjects in whom sulfonylurea (SU) therapy had failed. Subjects were switched to glipizide for 2 months (phase I) to confirm failure (fasting plasma glucose [FPG] 12.0 +/- 0.4 mmol/l) and then randomly assigned into three groups: BI-DSU; BI-no DSU; and DSU-no BI. During phase II (3 months), the BI dose was fixed (20 U/1.73 m2, low-dose). In phase III (3 months), BI was titrated up (high-dose) to achieve good control or until hypoglycemic symptoms prevented further dose increases. In phase IV (6 months), 25 of the 30 original subjects received open-labeled, high-dose BI-DSU. Low-dose BI-DSU markedly reduced FPG (13.6 +/- 0.8 to 8.0 +/- 0.6 mmol/l, P < 0.001), mean 24-h glucose (P < 0.001), HbA1c (8.9 +/- 0.7 to 7.6 +/- 0.3%, P = 0.07), and basal hepatic glucose production (HGP) (P < 0.005). A positive correlation (r = 0.69, P < 0.05) between the declines in FPG and HGP was observed. Neither low-dose BI alone nor DSU alone reduced FPG, mean 24-h glucose, HbA1c, or basal HGP. High-dose (40 +/- 5 U/day) BI plus DSU further reduced the FPG (6.3 +/- 0.6 mmol/l), HbA1c (7.1 +/- 0.3%), mean 24-h plasma glucose, and basal HGP (all P < 0.05 vs. phase II).(ABSTRACT TRUNCATED AT 250 WORDS)
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, and R. A. DeFronzo
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Diabetes Care, November 1, 2006; 29(11): 2371 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. C. Riddle, J. Rosenstock, and J. Gerich
The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Diabetes Care, November 1, 2003; 26(11): 3080 - 3086.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. E. DeWitt and I. B. Hirsch
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
JAMA, May 7, 2003; 289(17): 2254 - 2264.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
J. R. White Jr., S. N. Davis, R. Cooppan, M. B. Davidson, K. Mulcahy, G. A. Manko, and D. Nelinson
Clarifying the Role of Insulin in Type 2 Diabetes Management
Clin. Diabetes, January 1, 2003; 21(1): 14 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Wright, A.C. F. Burden, R. B. Paisey, C. A. Cull, and R. R. Holman
Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)
Diabetes Care, February 1, 2002; 25(2): 330 - 336.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. C. Riddle
Timely Addition of Insulin to Oral Therapy for Type 2 Diabetes
Diabetes Care, February 1, 2002; 25(2): 395 - 396.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Landstedt-Hallin, U. Adamson, and P.-E. Lins
Oral Glibenclamide Suppresses Glucagon Secretion during Insulin-Induced Hypoglycemia in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3140 - 3145.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
R. A. DeFronzo
Pharmacologic Therapy for Type 2 Diabetes Mellitus
Ann Intern Med, August 17, 1999; 131(4): 281 - 303.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. D. Wise, M. F. Nielsen, P. E. Cryer, and R. A. Rizza
Overnight Normalization of Glucose Concentrations Improves Hepatic But Not Extrahepatic Insulin Action in Subjects with Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2461 - 2469.
[Abstract] [Full Text]

Home page
 NEJMHome page
R. A. DeFronzo, A. M. Goodman, and The Multicenter Metformin Study Group
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
N. Engl. J. Med., August 31, 1995; 333(9): 541 - 549.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1995 by the American Diabetes Association.